Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX-471 · 1 trial · 3 indications
Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Incidence of treatment emergent adverse events (TEAEs), treatment-related AEs (TREAEs), and serious adverse events (SAEs)
Efficacy, exposure, safety events, and markers of response will be aggregated to select a Phase 2 dose
| Arm | Type | Description |
|---|---|---|
| Dose Level 0.3 mg/kg | EXPERIMENTAL | - |
| Dose Level 0.6 mg/kg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CTX-471 | DRUG | Patients will receive CTX-471 as an intravenous (IV) infusion every 2 weeks until disease progression or unacceptable toxicity. |
Inclusion Criteria: 1. Age 18 years or older. 2. Positive immunohistochemical staining for NCAM (defined as ≥ 1% of malignant cells with membranous/cytoplasmic staining of any intensity) on an archived (≤ 3 months) or freshly taken biopsy specimen (centrally tested) with histologically confirmed di...
CTX-471 is an investigational small molecule developed by Compass Therapeutics, Inc. (ticker CMPX) for the treatment of neuroendocrine neoplasms, a group of cancers that includes neuroendocrine tumors and neuroendocrine carcinomas. It is currently in Phase 2 clinical development and has not been approved by the FDA.
CTX-471 is being studied for use in patients with neuroendocrine neoplasms, including neuroendocrine tumors and neuroendocrine carcinomas. The Phase 2 trial enrolls adults aged 18 years and older with neural cell adhesion molecule (NCAM) positive disease. It remains investigational and is not approved for any indication.
CTX-471 targets CD137, a protein also known as 4-1BB that acts as a costimulatory receptor on immune cells. CD137 belongs to the tumor necrosis factor receptor family, and targeting it is intended to stimulate immune responses against tumor cells. CTX-471 is a small molecule directed at this protein target.
CTX-471 is being developed by Compass Therapeutics, Inc., which trades under the ticker CMPX. The company is the sponsor of the clinical program evaluating the drug in neuroendocrine neoplasms. No other developer or partnership for CTX-471 is disclosed in the available program information.
CTX-471 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 2 study is controlled and randomized, and it is not yet recruiting participants at this time.
CTX-471 is being evaluated in one clinical trial, NCT07684170, titled Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms. The Phase 2 trial has a planned enrollment of 58 participants, is randomized and controlled, and is currently listed as not yet recruiting.